B-Cell Non-Hodgkin’s Lymphoma: Epidemiology Forecast to 2027

B-Cell Non-Hodgkins Lymphoma: Epidemiology Forecast to 2027

Summary

Non-Hodgkins lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the patients immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the bodys inability to fight infections and other diseases. NHL accounts for 90% of all malignant lymphomas. NHL is one of the most prevalent hematologic cancers in adults and is more commonly diagnosed in developed countries. B-cell lymphomas are the most common form of NHL diagnosed in developed countries, making up approximately 80-85% of NHL cases in the US.

The epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and B-cell NHL incidence and prevalence. The epidemiologists applied country-specific incidence and prevalence rates of B-cell NHL, wherever available, to each countrys population to obtain the number of estimated diagnosed incident and prevalent cases.

The following data describes epidemiology of B-cell NHL cases. In 2017, the 7MM had 154,245 diagnosed incident cases of B-cell NHL. This is expected to increase to 183,052 diagnosed incident cases by 2027, at an Annual Growth Rate (AGR) of 1.87%. This increase is partly attributed to the moderately rising trend in incidence in the 7MM, combined with underlying demographic changes in the respective markets. In the 7MM, DLBCL was the most common subtype of B-cell NHL, followed by FL, MZL, and MCL. The US had the highest number of diagnosed incident and diagnosed prevalent cases of B-cell NHL. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

Scope

- The B-cell Non-Hodgkins Lymphoma (B-cell NHL) Epidemiology Report provides an overview of the risk factors and global trends B-Cell Non-Hodgkins Lymphoma in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of B-cell NHL; diagnosed prevalent cases of B-cell NHL; and diagnosed incident and prevalent cases of B-cell NHL types such as Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL) in these markets. Additionally, diagnosed incident cases of DLBCL, FL, MZL, and MCL are segmented according to Ann Arbor staging (stage I -IV). Diagnosed incident cases of FL based on grade (Grades 1-3) is also provided in this report.
- The B-cell NHL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The B-cell NHL Epidemiology report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global B-cell NHL market.
- Quantify patient populations in the global B-cell NHL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for B-cell NHL therapeutics in each of the markets covered.
- Understand magnitude of B-cell NHL market by subtypes such as DLBCL, FL, MZL, and MCL.

2 B-Cell NHL: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 US
3.3.2 5EU
3.3.3 Japan
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for B-Cell NHL (2017-2027)
3.5.1 Diagnosed Incident Cases of B-Cell NHL
3.5.2 Age-Specific Diagnosed Incident Cases of B-Cell NHL
3.5.3 Sex-Specific Diagnosed Incident Cases of B-Cell NHL
3.5.4 Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL
3.5.5 Diagnosed Incident Cases of DLBCL by Cancer Staging
3.5.6 Diagnosed Incident Cases of FL by Cancer Staging
3.5.7 Diagnosed Incident Cases of MZL by Cancer Staging
3.5.8 Diagnosed Incident Cases of MCL by Cancer Staging
3.5.9 Diagnosed Incident Cases of FL by Grade
3.5.10 Diagnosed Prevalent Cases of B-Cell NHL
3.5.11 Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer

List Of Tables

Table 1: B-Cell NHL Cancer Stages
Table 2: Risk Factors and Comorbidities for NHL

List Of Figures

Figure 1: 7MM, Diagnosed Incident Cases of B-Cell NHL, Both Sexes, Ages 18 Years, 2017 and 2027
Figure 2: 7MM, Age-Standardized Diagnosed Incidence of B-Cell NHL, Ages 18 Years, 2017
Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of B-Cell NHL, Ages 18 Years, 2017
Figure 4: Sources Used for Diagnosed Incident Cases of B-Cell NHL
Figure 5: Sources Used for Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL
Figure 6: Sources Used for Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL by Cancer Staging
Figure 7: Sources Used for Diagnosed Incident Cases of FL by Grade
Figure 8: Sources Used for Diagnosed Prevalent Cases of B-Cell NHL
Figure 9: Sources Used for Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL
Figure 10: 7MM, Diagnosed Incident Cases of B-Cell NHL, Men and Women, Ages 18 Years, 2017
Figure 11: 7MM, Age-Specific Diagnosed Incident Cases of B-Cell NHL, Men and Women, 2017
Figure 12: 7MM, Sex-Specific Diagnosed Incident Cases of B-Cell NHL, Men and Women, Ages 18 Years, 2017
Figure 13: 7MM, Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL, Men and Women, Ages 18 Years, 2017
Figure 14: 7MM, Diagnosed Incident Cases of DLBCL by Cancer Stage, Men and Women, Ages 18 Years, 2017
Figure 15: 7MM, Diagnosed Incident Cases of FL by Cancer Stage, Men and Women, Ages 18 Years, 2017
Figure 16: 7MM, Diagnosed Incident Cases of MZL by Cancer Stage, Men and Women, Ages 18 Years, 2017
Figure 17: 7MM, Diagnosed Incident Cases of MCL by Cancer Stage, Men and Women, Ages 18 Years, 2017
Figure 18: 7MM, Diagnosed Incident Cases of FL by Grade, Men and Women, Ages 18 Years, 2017
Figure 19: 7MM, Diagnosed Prevalent Cases of B-Cell NHL, Men and Women, 18 Years, 2017
Figure 20: 7MM, Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL, Men and Women, Ages 18 Years, 2017

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available